Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Iran has been developing at a steady pace in recent years.
Customer preferences: Iran has a high prevalence of hypertension, which has been attributed to factors such as urbanization, sedentary lifestyle, and unhealthy diets. As a result, there is a growing demand for anti-hypertensive drugs in the country. Iranian consumers tend to prefer generic drugs due to their lower cost compared to branded drugs.
Trends in the market: The Iranian government has been promoting the local production of pharmaceuticals to reduce the country's reliance on imports. This has led to the growth of the domestic pharmaceutical industry, including the production of anti-hypertensive drugs. In addition, the market has seen an increase in the use of combination therapies, where two or more drugs are used to treat hypertension. This trend is expected to continue as it has been found to be more effective in controlling blood pressure.
Local special circumstances: Iran is subject to economic sanctions that have limited the country's ability to import pharmaceuticals and raw materials. This has led to shortages of some drugs, including anti-hypertensive drugs, in the market. The government has responded by increasing investments in the domestic pharmaceutical industry to boost local production and reduce reliance on imports.
Underlying macroeconomic factors: Iran's healthcare sector has been growing in recent years, driven by factors such as population growth, urbanization, and an aging population. The government has been investing in the sector to improve healthcare access and quality, which has contributed to the growth of the pharmaceutical industry. In addition, the country's pharmaceutical market is expected to benefit from the implementation of universal health coverage, which will increase demand for drugs.Overall, the Anti-Hypertensive Drugs market in Iran is expected to continue to grow in the coming years, driven by factors such as the high prevalence of hypertension, the promotion of local production, and the growth of the healthcare sector. However, the market may face challenges due to economic sanctions and shortages of some drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
